Summit Therapeutics (SMMT) Total Liabilities (2017 - 2026)
Summit Therapeutics' (SMMT) quarterly Total Liabilities came in at $122.2 million in Q2 2026, up 89.17% YoY from $64.6 million in Q2 2025, and up 19.9% on a QoQ basis from $101.9 million in Q1 2026.
Summit Therapeutics (SMMT) Total Liabilities (2017 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 10 years of Total Liabilities data on file, last reported at $122.2 million in Q2 2026.
- Quarterly Total Liabilities rose 89.17% year-over-year to $122.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $122.2 million (up 89.17% YoY) and the FY2025 annual result came in at $92.3 million, up 97.22% from the prior year.
- Total Liabilities improved to $122.2 million in Q2 2026, from $101.9 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $537.5 million in Q4 2022 to a low of $22.1 million in Q3 2022.
- A 5-year average of $112.3 million and a median of $97.1 million in 2025 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities soared 1686.35% — and 2023, when it slumped 76.7%.
- Tracing SMMT's Total Liabilities over 5 years: stood at $537.5 million in 2022, then tumbled by 76.7% to $125.3 million in 2023, then plunged by 62.63% to $46.8 million in 2024, then soared by 97.22% to $92.3 million in 2025, then soared by 32.36% to $122.2 million in 2026.
- The last three Total Liabilities figures came in at $122.2 million (Q2 2026), $101.9 million (Q1 2026), and $92.3 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | 122.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 122.20 Mn |
| Mar 31, 2026 | 101.92 Mn |
| Dec 31, 2025 | 92.32 Mn |
| Sep 30, 2025 | 69.47 Mn |
| Jun 30, 2025 | 64.60 Mn |
| Mar 31, 2025 | 39.49 Mn |
| Dec 31, 2024 | 46.81 Mn |
| Sep 30, 2024 | 64.93 Mn |
| Jun 30, 2024 | 146.78 Mn |
| Mar 31, 2024 | 132.57 Mn |
| Dec 31, 2023 | 125.26 Mn |
| Sep 30, 2023 | 119.10 Mn |
| Jun 30, 2023 | 117.77 Mn |
| Mar 31, 2023 | 121.42 Mn |
| Dec 31, 2022 | 537.51 Mn |
| Sep 30, 2022 | 22.08 Mn |
| Jun 30, 2022 | 44.40 Mn |
| Mar 31, 2022 | 52.07 Mn |
| Dec 31, 2021 | 30.09 Mn |
| Sep 30, 2021 | 26.38 Mn |